[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100619949":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":10,"centralContacts":20,"locations":10,"responsibleParty":26,"collaborators":10,"id":29,"slug":30,"hasResults":31,"nctId":32,"briefTitle":33,"officialTitle":33,"acronym":10,"eligibilityCriteria":34,"healthyVolunteers":31,"sex":35,"minAge":36,"maxAge":10,"enrollmentInfo":37,"targetDuration":10,"studyType":40,"phases":10,"briefSummary":41,"conditions":42,"keywords":44,"overallStatus":54,"whyStopped":10,"lastUpdateSubmitDate":55,"lastUpdatePostDateStruct":56,"startDateStruct":59,"completionDateStruct":61,"leadSponsor":63,"locationsCount":10},{"fullName":5,"class":6},"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Study Cohort",null,"All enrolled participants undergo the same study procedures. This includes surgical resection of the renal cell carcinoma tumor, followed by multi-region sampling of intratumoral nodules for integrated multi-omics analysis (single-cell RNA sequencing, whole-exome sequencing, spatial transcriptomics) and the generation of patient-derived microtumor (PTC) models for ex vivo drug sensitivity testing.",[13],"Diagnostic Test: Multi-region Tumor Sampling and Integrated Multi-omics Analysis and Microtumor PTC Drug Sensitivity Assay",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":10},"DIAGNOSTIC_TEST","Multi-region Tumor Sampling and Integrated Multi-omics Analysis and Microtumor PTC Drug Sensitivity Assay","This integrated intervention involves: 1) Multi-region sampling of intratumoral nodules from resected RCC tumors for multi-omics analysis (single-cell RNA-seq, whole-exome sequencing, spatial transcriptomics) to map molecular and cellular heterogeneity. 2) Parallel generation of patient-derived microtumor (PTC) models from the same nodules for ex vivo drug sensitivity testing against a panel of oncology agents (e.g., Axitinib, Pembrolizumab). The core purpose is to correlate molecular features from omics with functional drug response data to decipher mechanisms of intra-tumoral heterogeneity and resistance.",[9],[21],{"name":22,"role":23,"phone":24,"phoneExt":10,"email":25},"Xiongjun Ye","CONTACT","8613910380916","yexiongjun@cicams.ac.cn",{"type":27,"investigatorFullName":22,"investigatorTitle":28,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","Chief Physician","100619949","multi-omics-analysis-of-renal-cell-carcinoma-mechanisms-drug-sensitivity-testing-in-patient-derived-cell-based-microtumors-100619949",false,"NCT07351266","Multi-omics Analysis of Renal Cell Carcinoma Mechanisms; Drug Sensitivity Testing in Patient-Derived Cell-based Microtumors","Inclusion Criteria:\n\n* Histologically confirmed renal cell carcinoma with regional lymph node metastasis.\n* Primary tumor with a maximum diameter ≥ 7 cm.\n* Tumor exhibits a multinodular distribution pattern on cross-section (assessed via intraoperative or postoperative gross specimen).\n* Age \\> 18 years.\n* Ability to understand the study and voluntarily provide written informed consent.\n\nExclusion Criteria:\n\n* Presence of distant metastasis (M1 stage).\n* Prior receipt of any targeted therapy or immunotherapy for renal cell carcinoma before surgery.\n* History of other active malignancies besides RCC (except cured basal cell carcinoma of the skin or carcinoma in situ of the cervix).\n* Any psychiatric, neurological, or legal condition that may compromise the ability to understand the informed consent or to comply with study procedures.","ALL","18 Years",{"count":38,"type":39},10,"ESTIMATED","OBSERVATIONAL","This is a research study aiming to better understand a type of kidney cancer called Renal Cell Carcinoma (RCC). Doctors have observed that inside some larger RCC tumors, there are multiple smaller nodules. This study wants to find out if these nodules are different from each other and how they might be related.\n\nTo do this, researchers will study tumor tissue samples from 10 patients with RCC who are having surgery. From each tumor, several nodules will be analyzed using advanced laboratory techniques. These techniques will create very detailed maps of the genes and cells within each nodule. At the same time, tiny 3D tumor models (called microtumors) will be grown from these samples in the lab to test how they respond to different cancer drugs.\n\nThe main goal is to combine these two types of information to see how the differences in genes and cells between nodules might explain why some tumors stop responding to treatment (become resistant). We hope this study will lead to a deeper understanding of how RCC grows and spreads, and help find new ways to diagnose and treat it in the future.",[43],"Renal Cell Carcinoma (Kidney Cancer)",[45,46,47,48,49,50,51,52,53],"Multi-omics","Single-Cell Sequencing","Spatial Transcriptomics","Whole Exome Sequencing","Microtumors","Patient-Derived Cells","Drug Sensitivity Testing","Tumor Heterogeneity","Intratumoral Nodules","NOT_YET_RECRUITING","2026-01-12",{"date":57,"type":58},"2026-01-20","ACTUAL",{"date":60,"type":39},"2026-01-25",{"date":62,"type":39},"2030-01-25",{"name":5,"class":6}]